lopinavir + ritonavir + tenofovir disoproxil fumarate

This drug is a combination of three antiretroviral agents: **lopinavir**, **ritonavir**, and **tenofovir disoproxil fumarate**. All are small molecule pharmaceuticals used primarily for the treatment of human immunodeficiency virus (HIV) infection. - **Lopinavir and ritonavir** are both HIV protease inhibitors; ritonavir is used mainly to boost the pharmacokinetic profile of lopinavir by inhibiting its metabolism via the CYP3A enzyme, increasing lopinavir plasma concentrations. - **Tenofovir disoproxil fumarate** is a nucleotide reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase, blocking viral DNA synthesis. When used together, these drugs target multiple points in the HIV replication cycle, reducing the viral load and slowing disease progression. This combination is used as part of combination antiretroviral therapy regimens for HIV-1 infection, particularly in antiretroviral-naive or -experienced patients. Typical use is oral administration, either as co-formulated tablets or as separately administered medicines[1][2][6][8].